Follistatin-344
Also called FS-344
No single human route established in this referenceHuman study reference
Research reference
Human study · different product
FS344 gene-delivery trial—not protein injections
One bilateral quadriceps gene-vector administration, measured in vector genomes/kg/leg
Follow-up through one year
Mendell et al., Mol Ther (2015) ↗When results may show
Follistatin-344
Evidence gap- When change was measured
- Walking and muscle-biopsy outcomes were studied in a small gene-delivery trial, not healthy-adult muscle gain.
- When to assess
- Follow-up through one year
- Conditions and limitations
- Six men with Becker muscular dystrophy. AAV1.CMV.FS344 gene delivery cannot establish an mg/mcg protocol for injected follistatin protein. No protein-vial starter or cycle is supported.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Mendell et al., Mol Ther (2015)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Mendell et al., Mol Ther (2015)AAV1.CMV.FS344 gene delivery cannot establish an mg/mcg protocol for injected follistatin protein. No protein-vial starter or cycle is supported.